AI Article Synopsis
- Circulating tumor DNA (ctDNA) is a promising biomarker in cancer management, serving as a liquid biopsy that helps in diagnosing and monitoring both localized and advanced solid tumors.
- ctDNA can provide critical information for prognosis, treatment decisions, and early detection of cancer recurrence, offering benefits over traditional imaging methods due to its quick response in reflecting disease changes.
- Various advanced techniques, like next-generation sequencing and droplet digital PCR, are used to detect ctDNA, though their effectiveness can be influenced by biological and technical factors.
Article Abstract
Circulating tumor DNA (ctDNA), often referred to as a liquid biopsy, represents a promising biomarker in the management of both localized and advanced solid tumors. It has garnered significant attention due to its potential to inform prognosis and guide therapeutic decisions. The clinical utility of ctDNA spans early cancer detection, minimal residual disease identification, recurrence surveillance, treatment monitoring, and precision oncology treatment decision-making in the advanced setting. Unlike conventional radiological assessments, the short half-life of ctDNA allows for more timely insights into disease dynamics. Several technological approaches are available to measure ctDNA, including next-generation sequencing and droplet digital polymerase chain reaction, although their clinical accuracy depends on multiple biological and technical factors. This review evaluates current evidence surrounding ctDNA's utility in early and advanced solid tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1146/annurev-med-100223-090016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!